Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial)
Status:
Not yet recruiting
Trial end date:
2022-01-15
Target enrollment:
Participant gender:
Summary
This study hypothesizes that the administration of Sodium zirconium cyclosilicate in CKD
patients with hyperkalemia while avoiding dietary potassium restriction will normalize their
serum potassium levels. Additionally, we aim to assess the effects of a high potassium diet
on renal function, endothelial function, acidosis, systemic inflammatory status and gut
microbiota.